HC Wainwright Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $75.00

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective cut by HC Wainwright from $80.00 to $75.00 in a research report released on Tuesday morning,Benzinga reports. They currently have a sell rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q1 2025 earnings at $2.35 EPS, Q2 2025 earnings at $2.64 EPS, Q3 2025 earnings at $2.73 EPS, Q4 2025 earnings at $2.84 EPS and FY2025 earnings at $10.54 EPS.

SRPT has been the subject of several other reports. Piper Sandler reduced their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. UBS Group upped their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Barclays decreased their price target on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Needham & Company LLC reduced their price objective on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating for the company in a report on Wednesday, November 27th. Finally, Evercore ISI cut their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $175.55.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $126.28 on Tuesday. The stock has a 50 day moving average of $122.61 and a two-hundred day moving average of $131.37. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a market cap of $12.06 billion, a P/E ratio of 101.22 and a beta of 0.77. Sarepta Therapeutics has a twelve month low of $85.61 and a twelve month high of $173.25.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors have recently made changes to their positions in SRPT. Innealta Capital LLC bought a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at $31,000. Nkcfo LLC bought a new position in Sarepta Therapeutics in the 2nd quarter valued at about $43,000. Sunbelt Securities Inc. raised its position in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 232 shares in the last quarter. Huntington National Bank lifted its holdings in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 175 shares during the period. Finally, Riggs Asset Managment Co. Inc. boosted its position in shares of Sarepta Therapeutics by 33.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 75 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.